VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Feb. 8, 2007) - Med BioGene Inc. (TSX VENTURE:MBI), an emerging biotechnology company developing genetic biomarkers for use in improving diagnosis, prognosis and treatment decisions for patients suffering from certain cancers and cardiovascular disease, is pleased to announce that it has received a $307,000 grant from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) to develop genetic biomarkers for cardiovascular disease (CVD).
